Figure 5

BCHE inhibited tumor development in a breast cancer orthotopic transplantation model. (a) Tumor volume and (b) body weight curves in mice subjected to treatment with PBS (oral gavage, once daily, n = 6), a low dose of BCHE (400 mg/kg, oral gavage, once daily, n = 6), a high dose of BCHE (800 mg/kg, oral gavage, once daily, n = 6), or paclitaxel (10 mg/kg, intraperitoneal injection, twice weekly, n = 6). (c) H&E staining of tissues from the major organs of BALB/c mice. The scale bar represents 50 µm. (d) IHC staining of tumor samples collected from the control and high-dose BCHE-treated groups. Scale bar = 50 µm. (e) Immunoblot analysis of GPX4 and transferrin expression in tumor tissues from the control, low-dose, and high-dose BCHE-treated groups. (f) Fe2+ content within tumor samples from the control, low-dose, and high-dose BCHE-treated groups. *P < 0.05, **P < 0.01, ***P < 0.001.